By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.
The Voice of People With Breast Cancer
Education
Educational Events
Understanding CDK4/6 Inhibitors in Breast Cancer Treatment
CDK4/6 inhibitors are an important treatment option for many people with hormone receptor–positive (HR+) breast cancer and are used in both early-stage and metastatic settings. In this webinar, a medical expert will explain what CDK4/6 inhibitors are, how they work, and the benefits they may offer. The session will also review common side effects associated with these treatments, strategies for managing them, and why treatment adherence is important. Participants will also learn how clinical trial data and treatment evidence are shared with patients to support informed decision-making and conversations with their healthcare team.
Expert Speaker:
Dr. Leena Hajra graduated from the University of Toronto, Faculty of Medicine in 2005. She subsequently went on to specialize in Internal Medicine and then Medical Oncology.
Dr. Hajra currently practices at Oak Valley Health in Markham, Ontario as a medical oncologist, with a focus on breast and gynecologic cancers. She is a lecturer and clinical teacher at the University of Toronto, Faculty of Medicine. Her current aspirations including developing a teaching program in Markham for medical students interested in community oncology. She is excited to lead and help launch the first cancer survivorship program at Oak Valley Heath.
Her driving force has always been and continues to be her family, husband and 2 sons.
When:
June 17, 2026 at 2 PM EDT
Where:
ONLINE
Who:
Anyone diagnosed with early-stage or metastatic HR+ breast cancer who is receiving or considering treatment with a CDK4/6 inhibitor.
Key Topic(s):
- What CDK4/6 inhibitors are and how they work
- The benefits of CDK4/6 inhibitors in early-stage and metastatic breast cancer
- Common side effects associated with treatment
- Strategies for managing treatment-related side effects
- The importance of treatment adherence
- Understanding and communicating clinical trial data with patients
To register click here.
This session is supported by an unrestricted educational grant from Lilly Canada.
SHARE
Our Stories
Events
Receive updates by email Subscribe Now
About CBCN
CBCN strives to voice the views and concerns of breast cancer patients through education, advocacy activities, and the promotion of information sharing.
Canadian Breast Cancer Network
185 Somerset St. West Suite 318, Ottawa, ON Canada K2P 0J2
Tel: 613-230-3044
Toll-free: 1-800-685-8820
Email Us
